Advanced search×

A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.

John D JD Hainsworth, Jeffrey R JR Infante, David R DR Spigel, Edward R ER Arrowsmith, Ralph V RV Boccia, and Howard A HA Burris

Cancer Invest 29(7):451-5 (2011) PMID 21696296

To evaluate the activity of panobinostat in refractory renal carcinoma.

DOI: 10.3109/07357907.2011.590568
Version: za2963e q8za1 q8zb2 q8zce q8zd2 q8zec q8zf3 q8zg9

Similar articles you may find interesting…

  1. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced ...
    J R JR Infante, R R Kurzrock, ... R S RS Herbst

    Cancer Chemother Pharmacol 69(1):165-72 (2012) PMID 21638123

    In part A, 29 patients received at least one dose of AZD4877 (5 mg, n = 4; 7.5 mg, n = 4; 10 mg, n = 3; 15 mg, n = 3; 20 mg, n = 3; 30 mg, n = 6; 36 mg, n = 3; 45 mg, n = 3). The MTD was defined as 30 mg, with the primary DLT being neutropenia. Although exposures appeared to...